Pernille Tine Jensen

Seksuel dysfunktion i menopausen. Status over forekomst, farmakologiske behandlingsmuligheder og risici

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Standard

Seksuel dysfunktion i menopausen. Status over forekomst, farmakologiske behandlingsmuligheder og risici. / Gregersen, Nina; Hilmand, Christina Bjerre; Jensen, Pernille Tine; Giraldi, Annamaria G Elena.

I: Ugeskrift for laeger, Bind 168, Nr. 6, 06.02.2006, s. 559-63.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Harvard

Gregersen, N, Hilmand, CB, Jensen, PT & Giraldi, AGE 2006, 'Seksuel dysfunktion i menopausen. Status over forekomst, farmakologiske behandlingsmuligheder og risici', Ugeskrift for laeger, bind 168, nr. 6, s. 559-63.

APA

Gregersen, N., Hilmand, C. B., Jensen, P. T., & Giraldi, A. G. E. (2006). Seksuel dysfunktion i menopausen. Status over forekomst, farmakologiske behandlingsmuligheder og risici. Ugeskrift for laeger, 168(6), 559-63.

CBE

Gregersen N, Hilmand CB, Jensen PT, Giraldi AGE. 2006. Seksuel dysfunktion i menopausen. Status over forekomst, farmakologiske behandlingsmuligheder og risici. Ugeskrift for laeger. 168(6):559-63.

MLA

Vancouver

Gregersen N, Hilmand CB, Jensen PT, Giraldi AGE. Seksuel dysfunktion i menopausen. Status over forekomst, farmakologiske behandlingsmuligheder og risici. Ugeskrift for laeger. 2006 feb 6;168(6):559-63.

Author

Gregersen, Nina ; Hilmand, Christina Bjerre ; Jensen, Pernille Tine ; Giraldi, Annamaria G Elena. / Seksuel dysfunktion i menopausen. Status over forekomst, farmakologiske behandlingsmuligheder og risici. I: Ugeskrift for laeger. 2006 ; Bind 168, Nr. 6. s. 559-63.

Bibtex

@article{709d51cac1144ad38601cefc383dd7e4,
title = "Seksuel dysfunktion i menopausen. Status over forekomst, farmakologiske behandlingsmuligheder og risici",
abstract = "The frequency of female sexual dysfunction increases with age, and the menopause has a negative influence on sexual life. Pharmacological treatment options of female sexual dysfunctions in the menopause include hormone therapy and sildenafil. Few randomised controlled studies have been done, and there is evidence suggesting that systemic hormone therapy, such as estrogen, estrogen/progesterone, estrogen/testosterone and tibolone, has a positive impact on sexual dysfunction in the menopause. There is evidence that local estrogen relieves vaginal dryness and dyspareunia. The recent discoveries of the side effects of hormone therapy necessitate careful evaluation of the indication for hormone therapy, and the duration of treatment is recommended to be as short as possible. The long-term side effects of testosterone in women have not yet been fully investigated. Sildenafil has shown a positive effect on female sexual dysfunction only in a limited group of women: those with arousal problems without desire problems. This result demands a focus on new pharmaceutical products, and at present the effect of testosterone and selective estrogen receptor modulators on female sexual dysfunction is being investigated.",
keywords = "Adult, Androgens/administration & dosage, Estrogen Receptor Modulators/administration & dosage, Estrogen Replacement Therapy/adverse effects, Female, Humans, Incidence, Libido/drug effects, Menopause/drug effects, Middle Aged, Norpregnenes/administration & dosage, Phosphodiesterase Inhibitors/administration & dosage, Piperazines/administration & dosage, Postmenopause/drug effects, Purines, Risk Factors, Sexual Dysfunction, Physiological/drug therapy, Sildenafil Citrate, Sulfones, Testosterone/administration & dosage",
author = "Nina Gregersen and Hilmand, {Christina Bjerre} and Jensen, {Pernille Tine} and Giraldi, {Annamaria G Elena}",
year = "2006",
month = feb,
day = "6",
language = "Dansk",
volume = "168",
pages = "559--63",
journal = "Ugeskrift for L{\ae}ger ",
issn = "0041-5782",
publisher = "Den Almindelige Danske L{\ae}geforening",
number = "6",

}

RIS

TY - JOUR

T1 - Seksuel dysfunktion i menopausen. Status over forekomst, farmakologiske behandlingsmuligheder og risici

AU - Gregersen, Nina

AU - Hilmand, Christina Bjerre

AU - Jensen, Pernille Tine

AU - Giraldi, Annamaria G Elena

PY - 2006/2/6

Y1 - 2006/2/6

N2 - The frequency of female sexual dysfunction increases with age, and the menopause has a negative influence on sexual life. Pharmacological treatment options of female sexual dysfunctions in the menopause include hormone therapy and sildenafil. Few randomised controlled studies have been done, and there is evidence suggesting that systemic hormone therapy, such as estrogen, estrogen/progesterone, estrogen/testosterone and tibolone, has a positive impact on sexual dysfunction in the menopause. There is evidence that local estrogen relieves vaginal dryness and dyspareunia. The recent discoveries of the side effects of hormone therapy necessitate careful evaluation of the indication for hormone therapy, and the duration of treatment is recommended to be as short as possible. The long-term side effects of testosterone in women have not yet been fully investigated. Sildenafil has shown a positive effect on female sexual dysfunction only in a limited group of women: those with arousal problems without desire problems. This result demands a focus on new pharmaceutical products, and at present the effect of testosterone and selective estrogen receptor modulators on female sexual dysfunction is being investigated.

AB - The frequency of female sexual dysfunction increases with age, and the menopause has a negative influence on sexual life. Pharmacological treatment options of female sexual dysfunctions in the menopause include hormone therapy and sildenafil. Few randomised controlled studies have been done, and there is evidence suggesting that systemic hormone therapy, such as estrogen, estrogen/progesterone, estrogen/testosterone and tibolone, has a positive impact on sexual dysfunction in the menopause. There is evidence that local estrogen relieves vaginal dryness and dyspareunia. The recent discoveries of the side effects of hormone therapy necessitate careful evaluation of the indication for hormone therapy, and the duration of treatment is recommended to be as short as possible. The long-term side effects of testosterone in women have not yet been fully investigated. Sildenafil has shown a positive effect on female sexual dysfunction only in a limited group of women: those with arousal problems without desire problems. This result demands a focus on new pharmaceutical products, and at present the effect of testosterone and selective estrogen receptor modulators on female sexual dysfunction is being investigated.

KW - Adult

KW - Androgens/administration & dosage

KW - Estrogen Receptor Modulators/administration & dosage

KW - Estrogen Replacement Therapy/adverse effects

KW - Female

KW - Humans

KW - Incidence

KW - Libido/drug effects

KW - Menopause/drug effects

KW - Middle Aged

KW - Norpregnenes/administration & dosage

KW - Phosphodiesterase Inhibitors/administration & dosage

KW - Piperazines/administration & dosage

KW - Postmenopause/drug effects

KW - Purines

KW - Risk Factors

KW - Sexual Dysfunction, Physiological/drug therapy

KW - Sildenafil Citrate

KW - Sulfones

KW - Testosterone/administration & dosage

M3 - Review

C2 - 16476214

VL - 168

SP - 559

EP - 563

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

SN - 0041-5782

IS - 6

ER -